These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

742 related articles for article (PubMed ID: 25146530)

  • 1. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.
    Lim HJ; Crowe P; Yang JL
    J Cancer Res Clin Oncol; 2015 Apr; 141(4):671-89. PubMed ID: 25146530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the PI3K-AKT-mTOR signaling network in cancer.
    Khan KH; Yap TA; Yan L; Cunningham D
    Chin J Cancer; 2013 May; 32(5):253-65. PubMed ID: 23642907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
    Barrett D; Brown VI; Grupp SA; Teachey DT
    Paediatr Drugs; 2012 Oct; 14(5):299-316. PubMed ID: 22845486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
    van der Ploeg P; Uittenboogaard A; Thijs AMJ; Westgeest HM; Boere IA; Lambrechts S; van de Stolpe A; Bekkers RLM; Piek JMJ
    Gynecol Oncol; 2021 Nov; 163(2):433-444. PubMed ID: 34253390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
    Burris HA
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis.
    Newton HB
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):105-28. PubMed ID: 14748662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
    Slomovitz BM; Coleman RL
    Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
    Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines.
    Lim HJ; Wang X; Crowe P; Goldstein D; Yang JL
    Anticancer Res; 2016 Nov; 36(11):5765-5771. PubMed ID: 27793898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
    Marty B; Maire V; Gravier E; Rigaill G; Vincent-Salomon A; Kappler M; Lebigot I; Djelti F; Tourdès A; Gestraud P; Hupé P; Barillot E; Cruzalegui F; Tucker GC; Stern MH; Thiery JP; Hickman JA; Dubois T
    Breast Cancer Res; 2008; 10(6):R101. PubMed ID: 19055754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-155 Affects Osteosarcoma MG-63 Cell Autophagy Induced by Adriamycin Through Regulating PTEN-PI3K/AKT/mTOR Signaling Pathway.
    Wang L; Tang B; Han H; Mao D; Chen J; Zeng Y; Xiong M
    Cancer Biother Radiopharm; 2018 Feb; 33(1):32-38. PubMed ID: 29412697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
    Pungsrinont T; Kallenbach J; Baniahmad A
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
    Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
    Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.
    LoRusso PM
    J Clin Oncol; 2016 Nov; 34(31):3803-3815. PubMed ID: 27621407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive review of the PTEN/PI3K/Akt axis in multiple myeloma: From molecular interactions to potential therapeutic targets.
    Alimohammadi M; Rahimzadeh P; Khorrami R; Bonyadi M; Daneshi S; Nabavi N; Raesi R; Farani MR; Dehkhoda F; Taheriazam A; Hashemi M
    Pathol Res Pract; 2024 Aug; 260():155401. PubMed ID: 38936094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.
    Nozhat Z; Hedayati M
    Mol Diagn Ther; 2016 Feb; 20(1):13-26. PubMed ID: 26597586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.
    Hernandez-Aya LF; Gonzalez-Angulo AM
    Oncologist; 2011; 16(4):404-14. PubMed ID: 21406469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
    Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
    Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications.
    Choudhury AD
    Prostate; 2022 Aug; 82 Suppl 1():S60-S72. PubMed ID: 35657152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
    Yi YW; Kang HJ; Kim HJ; Hwang JS; Wang A; Bae I
    Mol Carcinog; 2013 Sep; 52(9):667-75. PubMed ID: 22488590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.